{"name":"Sagimet Biosciences Inc.","slug":"sagimet-biosciences-inc","ticker":"","exchange":"","domain":"","description":"Sagimet Biosciences Inc. is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer and other diseases. The company has a diverse pipeline with nine drug candidates, including TVB-2640 and TVB-3567, which are in early clinical stages.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":39054000,"netIncome":-51038000,"cash":116482000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9jWjZjTTdDZ0JfRVltbmJtU0Jfd0pNMXUtcGhORjYwbjFxV2w0YjlEb0E2R0FhV1p3MzFBVUwxdVhsU0ZvWVdVV0V3UFJsZVluWklkZHlWNURWN2JSTHJ4TnRucF9FMHYyeEtpc3pR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan","headline":"If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT)","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-15","type":"pipeline","source":"simplywall.st","summary":"Don't Ignore The Insider Selling In Sagimet Biosciences - simplywall.st","headline":"Don't Ignore The Insider Selling In Sagimet Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxORXMtSE5oMjV5bVRyUXdtNUh2VDM5RnhMNUM1ZVU3a0JmTkhvdWEyQUZrVG5Xc0lzdVRLZGJ5aUpmS3J4UVIwaGg3TWJpdjV5SGVJLU5yVW8zWWUxcnFFMlRDaHRwcWQtZVpETnR3VFY3cWY0dm84Uy1rUFd3OURMTG9TVk00ZzJmczZpVlFKM19ndU81M2Z2dVhxaUZKNDBZWXdNYlZLaFRTTUxpblNYNWhnWQ?oc=5","date":"2026-02-03","type":"trial","source":"The Pharma Letter","summary":"New acne mechanism shows 1-year durability in Phase III, says Sagimet - The Pharma Letter","headline":"New acne mechanism shows 1-year durability in Phase III, says Sagimet","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQWlVPcGZwYmdjeldDaDQ0dVVGeWtTbmp4VUdvX2VaMXM1WnNRYlJ6VlJQQUZYcGx6eGRrLV9saWhYWDBpOUZiVXJJZ3FpRHlZRHhJbjU0cEd2SjhqR1Rwc1lhakZvbW54bzN0ZlBRQzhSWTc5TVM4WGVUT0JpRy13aXBFWVY4dkRFamhFaTlvLURpblBtazBvQlZUcjM1Qk40Xy1ncWVGYzhUTTI5ck1GeFQ5MkVwQQ?oc=5","date":"2026-02-02","type":"trial","source":"Stock Titan","summary":"Year-long acne pill study finds denifanstat well tolerated in 240 patients - Stock Titan","headline":"Year-long acne pill study finds denifanstat well tolerated in 240 patients","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQbkZPX3FBc0ItbjVKZFVta2F3eG5id2Q3eHBZenFLMHNpT2sxZVhXQmhoUFdzTF9Za0JpYUd4VzVKZ052V1pNYldNWEFtMEVoaThRbi1naHg0NGVkbjVZbVpjWFZyQzlYbzhGZTgzR09Ybk80UU56ejNORDBBQUxtQXROcUU2OW1maWdOM1dmMzctMC1VWTdWS1JnVDlWbGpCMzNZWlJJM1RCSlNyRTNzWGpYaUY?oc=5","date":"2026-01-30","type":"trial","source":"Seeking Alpha","summary":"Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT) - Seeking Alpha","headline":"Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT)","sentiment":"positive"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxNZ0ZIRXlIcjVRNXVFN09KZVQ2MHZWSzNtMFlidzlDUElYMEs0cUFDTTg5ZUgzNzNZOWlsNTdaazdxek9mNDJKeTIzZU45U2Z5Yzl0S0o3YkRPekNKM05IVE50aUZNWUZ2S1JGMWxTNnN5NEx2bVRWOTJaQ1IwLVFSMnVtb1V4a0ZjQnNjNWZDNFU3dTlyX0RCV2xJOXhKSWEwWmJacnlFRU5nSkVMNE45RWdRM0ZodlN1Z1dISmtCUU1aS2NwclRTcUJsNGlPLUxBQWpLclAxd3R3YUxOVzAzUHlsQ0RBYWFqOXo1cU13cHQyZ0VWaVg5aXhLMGpXZlFoZGZaNDlCcmUwWDVvNXdEUnV1WG5aUU5Oc0dEUGpjTnlOVTRZaXZnLTVJRXQyS1dBT3c2SG9iT0RZN3NUUzdr?oc=5","date":"2025-12-17","type":"deal","source":"GlobeNewswire","summary":"Sagimet Biosciences and TAPI Announce Global License - GlobeNewswire","headline":"Sagimet Biosciences and TAPI Announce Global License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPS0FYZXd1QVlUaHVwTlpFR0dVYUdXYThiRFJtRVhlMmk3TDdKS2hta3lMajlRX0xkR1pYMm02cGRiR3drdnN3anUxVi1fc3QzcDdwdjdDc251aDVBVzJYQUh1VWw5a2lST0RSYkNwdjBfdXowTEVHVmNVMjF6M2JPOE95T2I4YklLWkc3YUFBZ2MxV1Nsa0NCMEFn?oc=5","date":"2025-12-17","type":"deal","source":"Seeking Alpha","summary":"Sagimet rises as licensing deal with Teva unit targets Madrigal drug - Seeking Alpha","headline":"Sagimet rises as licensing deal with Teva unit targets Madrigal drug","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSW9kMXNZV2EwQmhjMlZjZmlGLUFvX1JxQ1RQUlU3TWZHTzhsb3VvdXdMQW5ZcFdHTmozNThieUxMTV82d1F4eUxtdkUyM005NVVGOVY5d0JreU12d0UxRERUeUtOVVNVZVRsSEFfWUxGUzRnNkQtTDg0RGZBTWZSQmg1Y3NtS1VsZXFVeHB2ZHk?oc=5","date":"2025-11-13","type":"earnings","source":"Yahoo Finance","summary":"Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Yahoo Finance","headline":"Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNRENaeGdGREJ4T2tBMjhoaEN0dUEtSHRDSFJ1N1VjUndLZXJ5OEdxbW85amlmS2dtVnY4Z1ZfSUo3QkgtQVd1UzlKMnB3WlYzRlFGcWtONG9qSnZTU0QxdGp4bkE3OG15M25KRkFoU1ZXVkgzc1JGaXFqQzVwaGhfdHdtOUxkR0lKY3ktNmZVRmNWd2VCV2RSSElLTUUxUEgwRkxkWmswRTlwTmRxVFlRVHQtcXVHQUhreXc?oc=5","date":"2025-11-13","type":"trial","source":"Quiver Quantitative","summary":"Sagimet Biosciences Provides Clinical Trial Updates and Financial Results for Q3 2025 - Quiver Quantitative","headline":"Sagimet Biosciences Provides Clinical Trial Updates and Financial Results for Q3 2025","sentiment":"positive"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2000000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":2000000,"period":"2023-12-31"},{"value":2000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":39054000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-51038000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":116482000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}